Human Genome’s lupus drug shows positive results in phase II
LymphoStat-B also significantly reduced disease activity across multiple clinical measures. In the mid-stage clinical trial, SLE patients given LymphoStat-B showed reduced disease activity after 52 weeks. Additionally, more